Michael Lee's most recent trade in IGM Biosciences Inc was a trade of 828 Common Stock done . Disclosure was reported to the exchange on June 30, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| IGM Biosciences Inc | Michael Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2025 | 828 | 12,712 (0%) | 0% | 0 | Common Stock | |
| Coherus Biosciences Inc | Michael Lee Ryan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 112,000 | 112,000 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Michael Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 55,000 | 55,000 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Michael Lee Milligan | See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 28 May 2025 | 400,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Michael Lee Milligan | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2025 | 400,000 | 400,000 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Michael Lee Milligan | See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 28 May 2025 | 85,391 | 0 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Michael Lee Milligan | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2025 | 85,391 | 85,391 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Michael Lee Milligan | See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 28 May 2025 | 41,250 | 0 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Michael Lee Milligan | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2025 | 41,250 | 41,250 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Michael Lee Milligan | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2025 | 38,234 | 38,234 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Michael Lee Milligan | See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 28 May 2025 | 38,234 | 0 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Michael Lee Milligan | See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 28 May 2025 | 28,675 | 0 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Michael Lee Milligan | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2025 | 28,675 | 28,675 | - | - | Stock Option (Right to Buy) | |
| Arhaus Inc - Ordinary Shar... | Michael Alan Lee | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2025 | 400,000 | 400,000 | - | - | Restricted Stock Units | |
| Five Star Bancorp | Lee Michael E. | SVP & Chief Regulatory Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 907 | 37,672 | - | 0 | Common Stock | |
| IGM Biosciences Inc | Michael Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 828 | 11,884 (0%) | 0% | 0 | Common Stock | |
| Neumora Therapeutics Inc. | Michael Lee Milligan | See Remarks | Sale of securities on an exchange or to another person at price $ 1.69 per share. | 18 Feb 2025 | 1,978 | 22,470 | - | 1.7 | 3,351 | Common Stock |
| Neumora Therapeutics Inc. | Michael Lee Milligan | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 400,000 | 400,000 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Michael Lee Milligan | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 85,391 | 85,391 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Michael Lee Milligan | See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2025 | 85,391 | 0 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Michael Lee Milligan | See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2025 | 41,250 | 0 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Michael Lee Milligan | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 41,250 | 41,250 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Michael Lee Milligan | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 38,234 | 38,234 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Michael Lee Milligan | See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2025 | 38,234 | 0 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Michael Lee Milligan | See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2025 | 28,675 | 0 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Michael Lee Milligan | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 28,675 | 28,675 | - | - | Stock Option (Right to Buy) | |
| IGM Biosciences Inc | Lee Michael | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2024 | 1,734 | 11,056 (0%) | 0% | 0 | Common Stock | |
| Five Star Bancorp | Michael E. Lee | SVP & Chief Regulatory Officer | Sale of securities on an exchange or to another person at price $ 30.67 per share. | 31 Oct 2024 | 1,500 | 36,765 | - | 30.7 | 46,008 | Common Stock |
| IGM Biosciences Inc | Michael Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2024 | 1,734 | 9,322 (0%) | 0% | 0 | Common Stock | |
| Five Star Bancorp | Michael E. Lee | SVP & Chief Regulatory Officer | Sale of securities on an exchange or to another person at price $ 29.09 per share. | 29 Jul 2024 | 3,000 | 38,265 | - | 29.1 | 87,268 | Common Stock |
| IGM Biosciences Inc | Michael Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2024 | 1,734 | 7,588 (0%) | 0% | 0 | Common Stock | |
| Shattuck Labs Inc | Michael Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 27,700 | 27,700 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Michael Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Coherus Biosciences Inc | Michael Lee Ryan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2024 | 112,000 | 112,000 | - | - | Stock Option (Right to Buy) | |
| IGM Biosciences Inc | Michael Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2024 | 1,734 | 5,854 (0%) | 0% | 0 | Common Stock | |
| IGM Biosciences Inc | Michael Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2024 | 29,400 | 29,400 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Lee Michael Milligan | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 41,250 | 41,250 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Michael Milligan Lee | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 20,625 | 24,448 | - | 0 | Common Stock | |
| Five Star Bancorp | Lee Michael E. | SVP & Chief Regulatory Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 6,000 | 41,265 | - | 0 | Common Stock | |
| IGM Biosciences Inc | Michael Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Dec 2023 | 492 | 4,120 (0%) | 0% | 0 | Common Stock | |
| Coherus Biosciences Inc | Michael Lee Ryan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 54,000 | 54,000 | - | - | Stock Option (Right to Buy) | |
| IGM Biosciences Inc | Michael Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 492 | 3,136 (0%) | 0% | 0 | Common Stock | |
| Fate Therapeutics Inc | Michael Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Shattuck Labs Inc | Michael Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2023 | 40,258 | 40,258 | - | - | Stock Option (Right to Buy) | |
| Five Star Bancorp | Michael E. Lee | SVP & Chief Regulatory Officer | Purchase of securities on an exchange or from another person at price $ 19.91 per share. | 27 Apr 2023 | 1,000 | 35,265 | - | 19.9 | 19,910 | Common Stock |
| IGM Biosciences Inc | Michael Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2023 | 15,500 | 15,500 | - | - | Stock Option (Right to Buy) | |
| IGM Biosciences Inc | Michael Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2023 | 492 | 2,644 (0%) | 0% | 0 | Common Stock | |
| Five Star Bancorp | Michael E. Lee | SVP & Chief Regulatory Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2023 | 387 | 34,265 | - | 0 | Common Stock | |
| IGM Biosciences Inc | Michael Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Dec 2022 | 230 | 2,152 (0%) | 0% | 0 | Common Stock | |
| IGM Biosciences Inc | Michael Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2022 | 230 | 1,922 (0%) | 0% | 0 | Common Stock | |
| IGM Biosciences Inc | Michael Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2022 | 230 | 1,692 (0%) | 0% | 0 | Common Stock | |
| Fate Therapeutics Inc | Michael Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 11,893 | 11,893 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Michael Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 8,650 | 11,331 (0%) | 0% | 0 | Common Stock | |
| IGM Biosciences Inc | Michael Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 230 | 1,462 (0%) | 0% | 0 | Common Stock | |
| IGM Biosciences Inc | Michael Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2022 | 29,497 | 29,497 | - | - | Stock Option (Right to Buy) | |
| Chavant Capital Acquisitio... | Michael Lee | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Feb 2022 | 3,652 | 24,348 | - | 0 | Ordinary Shares | |
| Five Star Bancorp | Michael E. Lee | SVP & Chief Regulatory Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2022 | 387 | 33,878 | - | 0 | Common Stock | |
| IGM Biosciences Inc | Michael Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2021 | 130 | 1,102 (0%) | 0% | 0 | Common Stock | |
| IGM Biosciences Inc | Michael Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 130 | 972 (0%) | 0% | 0 | Common Stock | |
| Shattuck Labs Inc | Michael Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2021 | 3,434 | 3,434 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Michael Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 4,334 | 4,334 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Michael Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 2,681 | 2,681 (0%) | 0% | 0 | Common Stock | |
| Five Star Bancorp | Michael E. Lee | SVP & Chief Regulatory Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2021 | 4,332 | 33,491 | - | 0 | Common Stock | |
| Five Star Bancorp | Michael E. Lee | SVP & Chief Regulatory Officer | Purchase of securities on an exchange or from another person at price $ 20.00 per share. | 04 May 2021 | 1,000 | 29,159 | - | 20 | 20,000 | Common Stock |
| IGM Biosciences Inc | Michael Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2021 | 130 | 842 (0%) | 0% | 0 | Common Stock | |
| IGM Biosciences Inc | Michael Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2021 | 6,423 | 6,423 | - | - | Stock Option (Right to Buy) | |
| Shattuck Labs Inc | Michael Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2020 | 1,286 | 1,286 | - | - | Stock Option (Right to Buy) | |
| Investcorp Credit Manageme... | Michael Lee Shaiman | Director | Purchase of securities on an exchange or from another person at price $ 5.07 per share. | 09 Dec 2020 | 500 | 1,000 (0%) | 0% | 5.1 | 2,536 | Common Stock |
| Investcorp Credit Manageme... | Michael Lee Shaiman | Director | Purchase of securities on an exchange or from another person at price $ 5.22 per share. | 04 Dec 2020 | 500 | 500 (0%) | 0% | 5.2 | 2,610 | Common Stock |
| IGM Biosciences Inc | Michael Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2020 | 178 | 534 (0%) | 0% | 0 | Common Stock | |
| Nikola Corp | Michael Lee Erickson | President, Nikola Powersports | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2020 | 283,017 | 653,290 | - | - | Stock Option (right to buy) | |
| Nikola Corp | Michael Lee Erickson | President, Nikola Powersports | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.06 per share. | 10 Sep 2020 | 283,017 | 283,017 | - | 1.1 | 299,998 | Common Stock |